Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00637273 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 514
- Enrollment target
NCT00637273 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 514 participants.
The verdict
NCT00637273, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 514 participants
- Enrollment target
Study Summary
This study will compare the benefits of exenatide once weekly treatment to those achieved by the approved antidiabetic therapies sitagliptin and pioglitazone in subjects whose type 2 diabetes is managed with metformin therapy alone. The safety and tolerability of the three treatment regimens will also be compared.
Interventions
- DRUG placebo tablet
- DRUG pioglitazone
- DRUG sitagliptin
- DRUG exenatide once weekly
- DRUG placebo once weekly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 514 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00637273
The ClinicalTrials.gov registry entry for NCT00637273 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 514 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which placebo tablet is the first listed.
NCT00637273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00637273 about?
NCT00637273 is a clinical study titled "A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)". This study will compare the benefits of exenatide once weekly treatment to those achieved by the approved antidiabetic therapies sitagliptin and pioglitazone in subjects whose type 2 diabetes is managed with metformin therapy alone. The safety and tolerability of the three treatment regimens will al...
What is the current status of trial NCT00637273?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 514 participants. The study started on 2008-01. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00637273?
The interventions under investigation include: placebo tablet (DRUG), pioglitazone (DRUG), sitagliptin (DRUG), exenatide once weekly (DRUG), placebo once weekly (DRUG).
Who is sponsoring clinical trial NCT00637273?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.